黑料网

Abstract

In contemporary medical research, the significance of quality of life assessment is increasingly acknowledged, particularly in the evaluation of therapies aimed at pain management. The impact of pain on overall quality of life is profound, affecting individuals across all demographics and pain types. Effective analgesic therapies, including opioids, cyclooxygenase (COX)-2 inhibitors (coxibs), and adjuvant analgesics for neuropathic pain, have demonstrated notable improvements in quality-of-life scores by alleviating pain. Coxibs, in particular, offer promising advantages in providing effective analgesia with fewer drawbacks compared to opioids. Recent studies, such as those involving the COX-2 inhibitor rofecoxib, have shown significant enhancements in quality of life for patients with conditions like osteoarthritis and chronic lower back pain. Quality-of-life measurements, especially symptom distress scales, serve as sensitive tools for discerning differences among analgesics within the same class. Moving forward, integrating quality of life as an outcome domain in pharmacotherapeutic research is imperative, alongside the conventional variables of efficacy and safety. In particular, future investigations concerning coxibs should incorporate symptom distress scores to delineate meaningful distinctions between this novel class of analgesics and no selective no steroidal anti-inflammatory drugs. This abstract underscores the evolving recognition of quality of life as a paramount parameter in pain management research and advocates for its comprehensive integration into future studies.